Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today announced its intention to offer shares of common stock (or pre-funded warrants in lieu thereof) through an underwritten public offering. All of the shares of common stock (or pre-funded warrants in lieu thereof) are being offered by the Company. The completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms. The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and...
"With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving...
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...
Kuala Lumpur, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hot Spring Enzyme Bath today announced the release of an official account from its founder, Pei Qian, detailing the personal circumstances that led to the creation of the wellness center in Kajang, Malaysia. The statement marks the first time the company has formally shared the narrative behind its formation.
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...
VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.
Charity auction raises $250,000 for Children's Miracle Network Hospitals
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Children's Miracle Network Hospitals (CMN Hospitals) announced that...
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —
— BRINSUPRI 10...
Tech-Powered Skincare Franchise Opens Six New Studios, Signs 11 New Leases, and Attracts Repeat Investment Across Key Markets
WASHINGTON, Aug. 12, 2025 /PRNewswire/ -- GLO30,...
With Three-Year Revenue Growth of 91%, this Marks the Company's 12th Appearance on the List
NASHVILLE, Tenn., Aug. 12, 2025 /PRNewswire/ -- Crown Laboratories, Inc., a...